Lupine Launches Generic Edarbi in the US with Exclusive 180 Days

Overview: Lupine Limited, a global pharmaceutical giant, has announced the official launch of its generic blood pressure medication in the US after winning the coveted approval from the US FDA. As an exclusive “first to file” company, Lupine will enjoy six months of competitive exclusivity in the generics market and will be positioned to capture a revenue pool worth $53.5 million.

Lupine Limited It is currently trading at Rs. 2295 after yesterday’s closing price of Rs. 2272. The stock opened at Rs. At 2283, it hit a daily high of Rs. 2299; Today’s current lowest price is Rs. 2279.2. The company’s current market capitalization is 100 billion won. ₹1,04,921 crore, with a price-to-earnings ratio of 18.2 times, lower than the peer average industry ratio of 31.7 times.

Lupine Limited announced that it has received Abbreviated New Drug Application (ANDA) approval from the US FDA and launched Azilsartan Medoxomil Tablets (40mg, 80mg) in the US.

The released product is a generic version of the branded drug Edarbi®, indicated for the treatment of high blood pressure in adults. According to IQVIA data, the reference drug recorded estimated annual sales of $53.5 million (approximately Rs. 445 million) in the US market in the 12 months to April 2026.

These products are manufactured through Lupin’s global manufacturing network, which includes 15 manufacturing facilities supporting production scale and supply continuity. The company said it is an exclusive “first to register” applicant for this product in the U.S., so it is eligible for a 180-day generic drug exclusivity period.

Under this framework, other generic manufacturers are not permitted to sell competing versions of the same drug in the United States for 180 days from the date of launch. During this period of exclusivity, the market is limited to the original brand product and the first registered generic version, subject to regulatory provisions on the approval of generic drugs.

In the absence of competing generic entrants, the exclusivity window generally limits the price pressure that a multiplayer generic market can experience. This allows the first-list manufacturer to operate without immediate price competition from other generic players during the initial launch phase.

Strengthening Lupin’s position in the US market

Lupine is a global pharmaceutical company with more than 24,000 employees and seven research centers across more than 100 markets. The launch of this product expands Lupin’s U.S. portfolio, particularly in the cardiovascular therapeutics segment. The Company’s established distribution network and existing relationships with healthcare providers and payers support the integration of new product offerings within the current commercial framework.

Recent Quarterly Performance

Featured in Financial Highlights, Lupine Limited Profit increased from 10 million won to 10 million won. 566.7 billion in the fourth quarter of fiscal 2025 to 747.5 billion in the fourth quarter of fiscal 2026, a significant growth of 31.90% year-on-year and also an increase in Rs. From Q3 FY26 to Q4 FY26, revenue stood at $716.8 billion, a marginal increase of 4.28%.

Net profit increased significantly from 100 million won. Net profit as of the third quarter of 2026 increased by 24.3% from Rs 118.1 billion in the third quarter of 2026 to Rs 146.9 billion in the fourth quarter of 2026, a significant increase of 87.85% year-on-year. Lupine Limited’s Over the past five years, sales and net profit have grown at a compound annual growth rate (CAGR) of 13% and 37%, respectively.

In terms of rate of return, ROE is 30.3% and ROE is 20.91%. The company’s earnings per share (EPS) is 100 billion won. As of the 4th quarter of FY26, it is 31.94 and the debt ratio is very low at 0.29x.

Lupine Limited, headquartered in Mumbai, India, sells its medicines in more than 100 countries. Lupine manufactures branded, generic, compounded, biotech, and active pharmaceutical ingredients. The company has strong positions in the respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women’s health sectors and is trusted by healthcare professionals and consumers globally. Lupine has 15 modern plants and 7 research centers worldwide and a dedicated workforce of more than 24,000 experts. Through its subsidiaries Lupine Diagnostics, Lupine Digital Health and Lupine Manufacturing Solutions, Lupine is committed to improving health outcomes for patients.

Disclaimer: The following opinions and investment tips are expressed by investment professionals/brokerage firms/rating agencies. tradebrains.in It is their own and not that of the website or its management. Investing in stocks carries the risk of financial loss. Therefore, investors must exercise appropriate caution while investing or trading in stocks. Neither Trade Brains Technologies Private Limited nor the author shall be liable for any loss suffered as a result of any decision taken based on this article. Consult your investment advisor before investing